It is the first FDA-approved test for the stem cell transplant use case and meets the WHO International Standard for comparable results.
The company currently offers target amplification assays for diagnostic use and clinical research that are based on a proprietary multiplex PCR technology.
The firm recently made strategic hires with commercialization experience in anticipation of bringing its handheld point-of-care device to market.
With the conditional approval, Rosetta can now market its assays to test for key mutations in lung, colon, and melanoma cancers in New York State.
Altona has validated the test on various PCR platforms, and it is now authorized for use as a molecular diagnostic on patient samples.
In Genome Research this week: transcriptomic analysis of the Venus flytrap, SMASH approach for CNV analysis, and more.
A Caltech professor wins the Millennium Technology Prize that lauds technological advances that improve human life.
San Diego's biotech scene has a dearth of executives who are women, Stat News reports.
Some 90 percent of respondents to a Nature survey say there is a research reproducibility crisis.